

To: [REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED]
Sent: Mon 1/4/2021 7:46:04 AM
Subject: FW: CEM_CMO_2020_044_JCVI_Statement.pdf
Received: Mon 1/4/2021 7:46:05 AM
[CEM_CMO_2020_044_JCVI_Statement.pdf](#)

Ha [REDACTED]

Ik zag in je slidedeck dat je rekent met 52% efficacy van 1 dose pfizer.

Ik heb het nog niet in detail bekeken, maar JCVI rekent met veel hogere effectiviteit van 1 dosis (zie bestand). Ze laten dan gevallen in de eerste week achterwege. Misschien goed om iig in je achterhoofd te houden, als er mensen over beginnen.

Groet,

[REDACTED]

QUOTE:

Published efficacy between dose 1 and 2 of the Pfizer vaccine was 52.4% (95% CI 29.5-68.4%). Based on the timing of cases accrued in the phase 3 study, most the vaccine failures in the period between doses occurred shortly after vaccination, the period before any immune response is expected. Using data for those cases observed between day 15 and 21, efficacy against symptomatic COVID-19 was estimated at 89% (95% CI 52-97%), suggesting that short term protection from dose 1 is very high from day 14 after vaccination. Similar findings were seen with the Moderna mRNA vaccine out to 108 days after the first dose (see Annex A).

From: [REDACTED] <[REDACTED]@hotmail.com>
Sent: vrijdag 1 januari 2021 20:54
To: [REDACTED] <[REDACTED]@rivm.nl>
Subject: CEM_CMO_2020_044_JCVI_Statement.pdf

Get [Outlook for Android](#)